Johnson & Johnson (JNJ) Receives Consensus Rating of “Buy” from Analysts

Johnson & Johnson (NYSE:JNJ) has earned an average recommendation of “Buy” from the sixteen research firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $144.45.

Several research firms have recently weighed in on JNJ. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price on the stock in a research report on Wednesday, March 27th. Barclays reissued an “equal weight” rating and issued a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Citigroup boosted their price objective on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research report on Monday, February 25th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Steinberg Global Asset Management lifted its stake in Johnson & Johnson by 33.8% in the first quarter. Steinberg Global Asset Management now owns 23,144 shares of the company’s stock valued at $2,966,000 after acquiring an additional 5,852 shares during the last quarter. Flagship Harbor Advisors LLC lifted its stake in shares of Johnson & Johnson by 5.9% in the first quarter. Flagship Harbor Advisors LLC now owns 28,592 shares of the company’s stock worth $3,996,000 after buying an additional 1,603 shares during the last quarter. Welch Group LLC lifted its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Welch Group LLC now owns 202,654 shares of the company’s stock worth $28,329,000 after buying an additional 3,764 shares during the last quarter. Horan Capital Management lifted its stake in shares of Johnson & Johnson by 0.3% in the first quarter. Horan Capital Management now owns 57,001 shares of the company’s stock worth $7,968,000 after buying an additional 161 shares during the last quarter. Finally, Arbor Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 109.8% in the first quarter. Arbor Investment Advisors LLC now owns 4,585 shares of the company’s stock worth $641,000 after buying an additional 2,400 shares during the last quarter. 67.29% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson stock opened at $136.52 on Tuesday. The company has a market capitalization of $362.76 billion, a PE ratio of 16.69, a PEG ratio of 2.07 and a beta of 0.68. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion for the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period last year, the firm posted $1.74 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has approved a share buyback plan on Monday, December 17th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 1.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is a Special Dividend?

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit